← All trials
NCT06092788
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2023
- Primary completion
- Dec 31, 2023
- Completion date
- Mar 31, 2024
- First posted
- Oct 23, 2023
- Last posted
- Oct 23, 2023
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ATXA Therapeutics LimitedLead sponsor
- Hammersmith Medicines ResearchCollaborator
- Hammersmith Medicines ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.